Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Power in Partneringover 2 years ago
The IRA Impact: Navigating Its Evolving Complexitiesover 2 years ago
Fighting for Innovationover 2 years ago
Say Hello to Flexible: Reimagining the Patient Journeyover 2 years ago
Aspiring for the C-Suite? Consider Being a Chief of Staffover 2 years ago
Latent Benefit of Access Restrictions for Rare Conditionsover 2 years ago
The Pharmaceutical Playbook for Asia’s Private Marketover 2 years ago
Operating Models for Successful DOL EngagementAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
5